GSK plc Stock price

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Delayed London Stock Exchange 11:35:07 2023-11-30 am EST Intraday chart for GSK plc 5-day change 1st Jan Change
1,419.40 GBX +1.31% -0.11% -1.27%
Sales 2023 * 29.62 B 37.43 B Sales 2024 * 31.15 B 39.37 B Capitalization 57.57 B 72.76 B
Net income 2023 * 5,490 M 6,938 M Net income 2024 * 5,641 M 7,129 M EV / Sales 2023 *
2,45x
Net Debt 2023 * 14.89 B 18.82 B Net Debt 2024 * 12.08 B 15.26 B EV / Sales 2024 *
2,24x
P/E ratio 2023 *
10,5x
P/E ratio 2024 *
10,1x
Employees 69,400
Yield 2023 *
4,06%
Yield 2024 *
4,33%
Free-Float 93.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.31%
1 week-0.11%
1 month-2.61%
3 months+2.20%
6 months+5.42%
Current year-1.27%
More quotes
1 week
1 395.00
Extreme 1395
1 428.60
1 month
1 371.40
Extreme 1371.4001
1 437.13
Current year
1 302.60
Extreme 1302.6
1 563.20
1 year
1 302.60
Extreme 1302.6
1 609.00
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 2010
Chief Tech/Sci/R&D Officer - 2017
Chief Tech/Sci/R&D Officer - 2017
Members of the board TitleAgeSince
Chairman 65 2019
Director/Board Member 64 2014
Director/Board Member 61 2017
More insiders
Date Price Change Volume
23-11-30 1,419.40 +1.31% 12,531,210
23-11-29 1,401.00 -0.76% 2,873,205
23-11-28 1,411.80 -0.17% 5,168,417
23-11-27 1,414.20 -0.59% 2,685,048
23-11-24 1,422.60 +0.11% 4,716,875

Delayed Quote London Stock Exchange, November 30, 2023 at 11:35 am EST

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
14.19GBP
Average target price
17.25GBP
Spread / Average Target
+21.50%
Consensus
1st Jan change Capi.
-1.27% 72 836 M $
+61.56% 532 B $
+48.29% 454 B $
-12.45% 372 B $
-7.63% 260 B $
-11.89% 251 B $
-18.74% 218 B $
+1.83% 201 B $
-9.73% 199 B $
-40.53% 172 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock GSK plc - London Stock Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer